Photo by atikahakhtar from unsplash
The clinical use of TNF-alpha inhibitors have been increasing in the treatment of autoimmune disorders. The most common anti-TNF-alpha agents on clinical use are ethanercept, infliximab and adalimumab. TNFalpha is… Click to show full abstract
The clinical use of TNF-alpha inhibitors have been increasing in the treatment of autoimmune disorders. The most common anti-TNF-alpha agents on clinical use are ethanercept, infliximab and adalimumab. TNFalpha is an important mediator in the pathogenesis of tuberculosis, therefore the use of TNFAI increases the risk of tuberculosis. Patients who are on anti-TNF alpha treatment should be carefully evaluated for tuberculosis risk before and during therapy. The recommended screening tools are detailed history, physical examination, tuberculin skin test and/or interferon gamma (IFN-γ) release assay and chest X-Ray every six months.
Journal Title: Clinical and Experimental Dermatology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!